Opella Asia, Middle East and Africa [AMEA]

Certified B Corporation
Standards version

1.6

Headquarters

Central Singapore Community Development Council, Singapore

Certified Since

January 2025

Industry

Pharmaceutical products

Sector

Manufacturing

Operates In

Australia,

China,

Egypt,

India,

Indonesia,

Japan,

Malaysia,

Philippines,

Saudi Arabia,

Singapore,

South Korea,

Tunisia,

Turkey,

United Arab Emirates,

Vietnam

Opella, the consumer healthcare unit of Sanofi, offers a diverse product line of over-the-counter medicines, and food supplements across several categories, including digestive health, cough and cold, and pain. Our strong portfolio of brands includes Eve, Telfast, Cenovis. Through our consumer-led, science-based products we enable people to champion better self-care and are investing in community well-being, because we believe healthier people and a healthier planet go hand in hand. As guardians of personal health, we are dedicated to growing our business while helping improve the health of people and the planet.

Overall B Impact Score

Based on the B Impact assessment, Opella Asia, Middle East and Africa [AMEA] earned an overall score of 87.5. The median score for ordinary businesses who complete the assessment is currently 50.9.
87.5
87.5 Overall B Impact Score
80 Qualifies for B Corp Certification
50.9 Median Score for Ordinary Businesses

Governance 10.7


Workers 29.1


Community 17.6


Environment 15.7


Customers 14.2



Additional Documentation

Opella AMEA Aggregated Transparent Assessment

Opella AMEA - Controversial Industry Statement (2025)

Opella AMEA - Score Aggregation Methodology & Brand List (2025)

Disclosure Report 2025